Oppenheimer raised the firm’s price target on HCA Healthcare (HCA) to $540 from $500 and keeps an Outperform rating on the shares. The firm notes HCA reported strong Q4 2025 results, driven by solid margins. Following the quarter, HCA issued FY26 adjusted EBITDA guidance of $15.55B-$16.45B.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on HCA:
- HCA Healthcare price target raised to $588 from $525 at Cantor Fitzgerald
- HCA Healthcare price target raised to $550 from $500 at KeyBanc
- HCA Healthcare price target raised to $551 from $494 at Barclays
- HCA Healthcare Earnings Call: Growth Amid Policy Strain
- HCA Healthcare price target raised to $540 from $485 at BofA